Sigenex Oxford Ltd
Registered name: SIGENEX OXFORD LTD
Sigenex Oxford Ltd made £0 revenue and a £52.9k loss in the year to 31 May 2025.
Sigenex Oxford Ltd’s revenue was £0 in the year to 31 May 2025, with a loss of £52.9k and 1 employee. The company is classified under “research and experimental development on biotechnology” and is based in Oxford.
- Status
- Active
- Location
- Oxford, South East
- Age
- 2 yrs · since 2024
- Type
- Private Limited Company
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 May 2025 |
|---|---|
| Disclosure | Full P&L |
| Profit & loss | |
| Revenue (turnover) | £0 |
| Profit after tax | −£52.9k |
| Profit (best available) | −£52.9k |
| Staff costs | £17.6k |
| Employees (average) | 1 |
| Ratios | |
| Profit margin | — |
| Revenue per employee | £0 |
| Profit per employee | −£52.9k |
| Balance sheet — indirect signals, not revenue | |
| Net assets | £3.7k |
| Fixed assets | £2.4k |
| Current assets | £1.3k |
| Source | FullAccounts · bulk data Feb 2026 |
How the business works
- Profit margin
- —
- Profit ÷ revenue.
- Gross margin
- —
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £0
- Revenue ÷ average employees.
- Profit per employee
- −£52.9k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- —
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- —
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now £3.7k
- Cash at bank
- —
- Now —
- Headcount
- —
- Now 1
- Deferred income
- —
- Now —
- Fixed assets
- —
- Now £2.4k
Similar profitable businesses
- Astex Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £404m
- Profit
- £283m
- Staff
- 183
- Amphista Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £33.9m
- Profit
- £19.8m
- Staff
- 56
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
- Qiagen Manchester LimitedManchester · Research and experimental development on biotechnology
- Revenue
- £53.7m
- Profit
- £11.8m
- Staff
- 239
- Alchemab Therapeutics LtdLondon · Research and experimental development on biotechnology
- Revenue
- £30m
- Profit
- £8.3m
- Staff
- 55
- Ligand UK Development LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £8.7m
- Profit
- £6m
- Staff
- —
Sources
Latest figures from FullAccounts for the year to 31 May 2025 (profit −£52.9k), from the Companies House accounts bulk data published Feb 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.